Details for New Drug Application (NDA): 211150

✉ Email this page to a colleague

NDA 211150 describes WAKIX, which is a drug marketed by Harmony and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the WAKIX profile page.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this compound. Additional details are available on the pitolisant hydrochloride profile page.

Summary for 211150

Tradename:	WAKIX
Applicant:	Harmony
Ingredient:	pitolisant hydrochloride
Patents:	3

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 211150

Generic Entry Date for 211150^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH NARCOLEPSY Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 211150

Mechanism of Action	Cytochrome P450 3A4 Inducers Histamine H3 Receptor Antagonists Histamine H3 Receptor Inverse Agonists

Suppliers and Packaging for NDA: 211150

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150	NDA	Harmony Biosciences, LLC	72028-045	72028-045-03	1 BOTTLE, PLASTIC in 1 CARTON (72028-045-03) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150	NDA	Harmony Biosciences, LLC	72028-178	72028-178-03	1 BOTTLE, PLASTIC in 1 CARTON (72028-178-03) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 4.45MG BASE
Approval Date:	Aug 14, 2019	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Aug 14, 2026
Regulatory Exclusivity Use:	INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
Regulatory Exclusivity Expiration:	Aug 14, 2024
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:	Jun 21, 2027
Regulatory Exclusivity Use:	NEW PATIENT POPULATION

Expired US Patents for NDA 211150

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019	⤷ Sign Up	⤷ Sign Up
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019	⤷ Sign Up	⤷ Sign Up
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019	⤷ Sign Up	⤷ Sign Up
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.